Schools and authorized groups may use epinephrine delivery devices

Students may carry and self-administer an approved epinephrine delivery system. This applies to students in public and nonpublic schools while they are on school property or attending school-sponsored events. A parent or legal guardian must provide the required written authorization and medical information. A physician or authorized agent must confirm that the student was taught how to use the medication. Permission lasts only for the school year in which it is granted, although it may be renewed if all requirements are met. This provision applies beginning October 1, 2026, when the act takes effect.

Public schools may keep epinephrine delivery systems available, and school nurses or trained unlicensed staff may give them to students. This applies to K-12 public schools, their nurses, and unlicensed personnel who complete the required anaphylaxis training. A local school board may work with a physician to create an emergency response protocol. The devices must be FDA-approved and contain a premeasured dose of epinephrine. The requirement to secure and maintain a supply at each public school campus is enforced only if the state provides funding. Training may be online or in person and must cover warning signs, storage and use, and follow-up care. The provisions apply beginning October 1, 2026; the campus supply requirement applies only when state funding is provided.

Authorized organizations may obtain, store, provide, and administer epinephrine delivery systems during suspected anaphylaxis emergencies. This covers organizations other than K-12 public schools, including child care facilities, colleges, recreation camps, workplaces, restaurants, and sports venues. A medical practitioner must prescribe the devices in the organization's name, and the prescription lasts two years. Designated employees or agents must complete initial training and repeat it at least every two years. Trained personnel may provide or administer epinephrine when they believe in good faith that someone is experiencing anaphylaxis, even without a prescription or prior allergy diagnosis. Organizations must store the devices as directed, report administration incidents to the Department of Public Health, and follow any applicable reporting rules. These provisions apply beginning October 1, 2026.